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Abstract
Background: Lipid raft domains form in plasma membranes of eukaryotic cells by the tight packing
of glycosphingolipids and cholesterol. Caveolae are invaginated structures that form in lipid raft
domains when the protein caveolin-1 is expressed. The Chlamydiaceae are obligate intracellular
bacterial pathogens that replicate entirely within inclusions that develop from the phagocytic
vacuoles in which they enter. We recently found that host cell caveolin-1 is associated with the
intracellular vacuoles and inclusions of some chlamydial strains and species, and that entry of those
strains depends on intact lipid raft domains. Caveolin-2 is another member of the caveolin family
of proteins that is present in caveolae, but of unknown function.
Methods: We utilized a caveolin-1 negative/caveolin-2 positive FRT cell line and laser confocal
immunofluorescence techniques to visualize the colocalization of caveolin-2 with the chlamydial
inclusions.
Results: We show here that in infected HeLa cells, caveolin-2, as well as caveolin-1, colocalizes
with inclusions of C. pneumoniae (Cp), C. caviae (GPIC), and C. trachomatis serovars E, F and K. In
addition, caveolin-2 also associates with C. trachomatis serovars A, B and C, although caveolin-1 did
not colocalize with these organisms. Moreover, caveolin-2 appears to be specifically, or indirectly,
associated with the pathogens at the inclusion membranes. Using caveolin-1 deficient FRT cells, we
show that although caveolin-2 normally is not transported out of the Golgi in the absence of
caveolin-1, it nevertheless colocalizes with chlamydial inclusions in these cells. However, our
results also show that caveolin-2 did not colocalize with UV-irradiated Chlamydia in FRT cells,
suggesting that in these caveolin-1 negative cells, pathogen viability and very likely pathogen gene
expression are necessary for the acquisition of caveolin-2 from the Golgi.
Conclusion: Caveolin-2 associates with the chlamydial inclusion independently of caveolin-1. The
function of caveolin-2, either in the uninfected cell or in the chlamydial developmental cycle,
remains to be elucidated. Nevertheless, this second caveolin protein can now be added to the small
number of host proteins that are associated with the inclusions of this obligate intracellular
pathogen.
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Background
The Chlamydiaceae are gram-negative obligate intracellular
bacterial pathogens that replicate entirely within mem-
brane bound inclusions that develop from the phagocytic
vacuoles in which they enter. By mechanisms not under-
stood in detail, inclusions avoid fusing with endosomes
or lysosomes that might destroy the pathogen [1-3].
Instead, the inclusions provide an intracellular niche in
which the pathogen can survive and complete its develop-
mental cycle. The initial pathogen-containing endocytic
vacuoles co-associate with microtubules, and dynein, and
traffic to a perinuclear region, ultimately residing at the
microtubule organizing center and in close proximity to
the Golgi [4,5]. Here, they intercept exocytic vesicles of the
biosynthetic pathway that are derived from the Golgi and
continue their developmental cycle [6-9].
There are two genera in the family of Chlamydiaceae [10].
The genus Chlamydia is comprised of the C. trachomatis
species, which contains human pathogens, as well as the
mouse and swine strains, C. muridarum and C. suis respec-
tively, while the Chlamydophila genus is more diverse, con-
sisting of six species. Of these, C. pneumoniae, and C.
psittaci are relevant in human diseases. C. trachomatis is
primarily a pathogen of humans, containing the trachoma
biovariant (biovar), and the lymphogranuloma biovar
(LGV). The mouse pneumonitis agent (MoPn), frequently
used in vaccine work [11,12], is now classified separately
as C. muridarumn [10]. Some serological variants (serov-
ars) of the trachoma biovar primarily infect the urogenital
tract (e.g., E, K, and F) and are the major cause of signifi-
cant venereal disease in the United States [13]. Other, tra-
choma serovars primarily infect the conjunctiva (e.g., A, B,
and C), causing trachoma, the major form of preventable
blindness, worldwide [14]. The LGV biovar also causes
chronic venereal disease, which differs clinically from the
sexually transmitted disease caused by strains of the tra-
choma biovar. C. pneumoniae, another human pathogen,
is now implicated in atherosclerosis and cardiac disease,
as well as respiratory infection [15,16]. C. psittaci prima-
rily infects birds, but can also cause disease in humans.
The mechanism by which chlamydiae enter host cells is
not well defined, largely because of conflicting reports
that these organisms can enter by both clathrin-depend-
ent, as well as clathrin-independent pathways. Recently,
we examined the entry mechanisms of representative
members of each of the above Chlamydia species and bio-
vars. Our concern was whether their entry might be medi-
ated by the cholesterol and sphingolipid enriched micro-
domains in host cell plasma membranes known as lipid
rafts [17]. Application of biochemical criteria and confo-
cal microscopy demonstrated that five of the ten strains
we examined indeed enter by a mechanism that is
dependent on intact lipid rafts [18,19]. These strains
included C. trachomatis serovars E, F, and K, C. pneumoniae
(strain AR39), and C. caviae (Guinea Pig Inclusion Con-
junctivitis strain; GPIC). In contrast , C. trachomatis serov-
ars A, B, C, biovar LGV (L2 strain), and MoPn do not enter
via lipid rafts.
Caveolae are now considered to be a specialized kind of
lipid raft. These 50–100 nm flask-shaped invaginations
form in lipid rafts when the caveolae marker protein, cave-
olin-1, is expressed [reviewed in [20]]. In contrast, lipid
rafts are ubiquitous entities that form regardless of caveo-
lin-1 expression. The inclusion membranes of all of the
chlamydial strains that entered via lipid rafts, as indicated
by biochemical criteria, also appeared to acquire caveolin-
1 at entry, and accumulated more of the protein during
development in caveolin-1 expressing HeLa cells [18,19].
In contrast to the strains that entered by a raft-dependent
process, none of the other strains examined acquired cave-
olin-1 at entry.
The fact that entry of some chlamydial strains is depend-
ent on lipid rafts in general, rather than on the more spe-
cialized caveolae, was demonstrated using Fischer Rat
Thyroid (FRT) cells, which do not express caveolin-1 or
form caveolae. All ten strains that we examined were able
to enter the caveolin-1 negative FRT cells, but not if those
cells were treated with pharmacological agents that specif-
ically disrupt lipid rafts [19].
The Golgi is a likely source of most caveolin-1 on the
inclusions of those strains entering via lipid rafts. This is
suggested by the fact that caveolin-1 immunostaining of
those inclusions actually increases as they enlarge and
mature, and is consistent with reports that caveolin-1 first
becomes associated with raft domains in the Golgi, and
subsequently is transported to the plasma membrane on
vesicles derived from the Golgi [21-23]. Moreover,
chlamydial inclusions are known to intercept vesicles of
the biosynthetic pathway that originate from the Golgi,
from which they acquire sphingolipids and perhaps other
nutrients as well[6,7]. However, since inclusions of all
strains appear to acquire sphingolipids from the Golgi,
whereas only a subset of strains acquires caveolin-1, there
may be more than one sorting process and class of vesicles
with which Chlamydia can interact.
The caveolin gene family also contains caveolin-2 [24]
which has 38% sequence identity with caveolin-1 and
58% similarity. Caveolin-1 and -2 are co-expressed in
most cells, in which they form hetero-oligomeric com-
plexes. These complexes form in the endoplasmic reticu-
lum (ER), becoming associated with lipid rafts in the
Golgi, from which they are transported to the plasma
membrane. All of the putative functions of caveolae are
thus far associated with caveolin-1, and the function ofBMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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caveolin-2 is essentially unknown. Importantly, unlike
caveolin-1, caveolin-2 can not induce caveolae to form in
lipid rafts. An experimental finding that is particularly rel-
evant to the current study is that caveolin-2 can not exit
the Golgi in caveolin-1 negative FRT cells. However, it can
exit when recombinant caveolin-1 is expressed [25,26].
Thus, formation of hetero-oligomeric complexes of cave-
olin-1 and -2 facilitates transport of caveolin-2 out of the
Golgi and its sorting to the plasma membrane.
In the present study, we ask whether caveolin-2, like cave-
olin-1, might be associated with inclusions formed by
particular chlamydial strains. Unexpectedly, we found
that in HeLa cells, caveolin-2 was associated with inclu-
sions of strains that did not enter via lipid rafts and that
did not acquire caveolin-1 either at entry or at later times.
These strains included C. trachomatis serovars A, B, and C.
In the same cells, inclusions of C. trachomatis serovars E, F,
and K, C. pneumoniae (A39), and C. caviae (GPIC) were
marked by both of the caveolin proteins. Each of these
eight strains acquired caveolin-2 even in caveolin-1 nega-
tive FRT cells. In addition, the ability of each of these
strains to acquire caveolin-2 in the FRT cells was depend-
ent on pathogen gene expression. Thus, chlamydiae
appear to activate or induce an additional pathway for the
transport of caveolin-2 that is independent of caveolin-1.
Inclusions of two strains, LGV (L2) and MoPn, were not
marked by either caveolin-1 or -2.
Methods
Chlamydial strains
C. pneumoniae AR39 (Cpn), C. caviae, Guinea Pig Inclu-
sion Conjunctivitis (GPIC strain), C. trachomatis serovars
A/Har-13, Har-36B, C/TW-3, E/VW-KX, F, K/VR887,
mouse pneumonitis agent, (MoPn) and Lymphogranu-
loma venereum, (LGV 434) were grown in HeLa 229 cells
without centrifuge assistance. Infectious elementary bod-
ies (EBs) were purified by renografin (Squibb diagnostics,
New Bronswick, NJ) density gradient centrifugation; alter-
natively lysates from infected cells were used to infect
monolayers.
Cell lines used
HeLa 229 cells were obtained from the American Type
Culture collection. Fischer rat thyroid (FRT) cells were a
gift from Dr. Michael P. Lisanti (Albert Einstein College of
Medicine, Bronx, NY). Cells were grown in minimum
essential medium with insulin (IMEMZO, Irvine Scien-
tific, Santa Ana, CA) with 5% fetal bovine serum (FBS,
Atlanta Biologicals, Norcross, GA.).
Immunostaining of Chlamydia infected cells
HeLa 229 or FRT cells were grown to confluence on 12
mm coverslips in 24 well plates (Becton Dickinson
Labware, Franklin Lakes, NJ). The cells were infected using
the various chlamydial strains listed above at an MOI of
3.0 in complete cycloheximide overlay media (Bio-Whit-
taker, Walkersville, Md.) containing 10% FBS, 1X L-
glutamine (CCOM) for 48 h at 37°C and 5% CO2. Cov-
erslips with the cell monolayers were harvested, rinsed
with phosphate buffered saline (PBS), fixed with 70%
cold methanol, stored and subsequently immunostained
following protocols similar to that described in detail pre-
viously [18,19]. Briefly, infected cells were immunos-
tained with a guinea pig anti-chlamydia polyclonal
antibody (Biomedia, Foster City, CA) and the monoclonal
mouse anti-caveolin-2 antibody (Transduction Laborato-
ries, Lexington, KY) for 1 h at 37°C. Following 4 washes
with PBS, the bound antibodies were detected using a
1:50 dilution of TRITC-conjugated goat anti-guinea pig
and FITC-conjugated goat anti-mouse secondary antibod-
ies (Jackson Immuno Research, West Grove, PA). Follow-
ing incubation for 1 h at RT and 4 rinses with (PBS),
coverslips were mounted onto slides using Fluoromount-
G (Southern Biotechnology Associates Inc., Birmingham,
AL). Slides were examined at 600X using a Bio-Rad MRC-
600 Laser Confocal Microscope system. Images were cap-
tured and as relevant, merged using the Confocal Assist-
ant™ version 4.02 Image Processing Software.
UV-treatment of EBs and infection of HeLa and FRT cells
C. trachomatis serovars A, B, C, E, F, LGV, C. muridarum
(MoPn), C. caviae (GPIC), and C. pneumoniae EB concen-
trates were exposed to short wavelength ultraviolet light
for 1 h in a Biosafety hood. A portion of the EBs used was
removed before UV treatment to serve as a control for ini-
tial viability. The EBs were then diluted in CCOM to an
MOI of 4.0 per cell and used to infect HeLa 229 and FRT
cells grown to confluence on 12 mm coverslips in 24 well
plates. Plates were incubated for 2 h at 37°C and 5% CO2.
After the 2 h incubation, the inoculum was removed and
replaced with fresh CCOM; cells were then re-incubated
for 34 h. At the end of the incubation period, the cover-
slips with cells were rinsed with sterile PBS and fixed with
methanol for 10 minutes as detailed above. Following fix-
ation, the cells were immunostained with a polyclonal
guinea pig anti-chlamydia and mouse monoclonal anti-
caveolin-2 antibodies as described above. FITC-conju-
gated goat anti-mouse and TRITC-conjugated goat anti-
guinea pig secondary antibodies were used respectively to
visualize the caveolin-2 and EBs within the cells. Slides
were examined at 600X with a Laser Confocal Microscope
system and images processed as described above.
Western blot of purified EBs and anti-Caveolin-2
C. trachomatis serovar K and C. pneumoniae AR39 purified
EBs were electrophoresed on a 4–12% NuPAGE gel (Inv-
itrogen Life technologies, Carlsbad, CA) using MES run-
ning buffer. The separated proteins were transferred to a
PVDF membrane at 25 V for 1 h using a 1X Novex® TrisBMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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Glycine buffer with 20% methanol in the XCell II™ Blot
Module and a XCell Surelock™ Mini-Cell apparatus (Invit-
rogen). The blot was then rinsed with 0.1% BSA/PBS,
blocked with 5% non-fat dry milk for 3 h, then rinsed and
cut into two. One half was stained with a 1:200 dilution
of mouse monoclonal anti-caveolin-2 antibody (Trans-
duction Labs, Lexington, KY), while the second half was
stained with a 1:100 dilution of a rabbit anti-Chlamydia
for 2 h with shaking. The blot was then rinsed and a
1:1000 dilution of AP-conjugated goat anti-mouse sec-
ondary antibody added and incubated for 1 h at RT. Fol-
lowing several washes, a BCIP/NBT alkaline phosphatase
substrate was added and the color allowed to develop.
Results
Caveolin-2 on chlamydial inclusions in caveolin-1 positive 
HeLa cells
We asked whether caveolin-2 might be associated with the
inclusions of each of the ten chlamydial strains and spe-
cies that we had previously assessed for raft-mediated
entry and for inclusion-associated caveolin-1 [19]. We
began by looking at infections in caveolin-1 positive HeLa
cells. Inclusions of C. trachomatis serovars E, F, and K, C.
pneumoniae (A39), and C. caviae (GPIC), previously were
seen to enter HeLa cells via lipid rafts, and their inclusions
were marked by caveolin-1 in those cells (ibid). Immu-
nostaining with caveolin-2 specific monoclonal antibod-
ies demonstrated that in HeLa cells, inclusions of each of
these strains also were marked by caveolin-2 (Figure 1,
Table 1). As in the case of caveolin-1 [19], optical sections
through the Z-axis clearly indicated the caveolin-2 as
packets associated with the vacuolar membrane (Figure
2). The disappearance of the caveolin-2 staining as the
depth of the optical sections increased, with no change in
the anti-Chlamydia staining, confirms that the caveolin-2
proteins are associated with the vacuolar membranes of
these inclusions and are not associated with the individ-
ual EBs and RBs inside of the chlamydial vacuole. This
profile is similar to that seen when Z-sections were taken
of the caveolin-1 staining.
Importantly, immunostaining for caveolin-2 appears
nonrandom on the inclusion membrane (Figure 2, Z sec-
tion #1). Indeed, the series of merged optical sections
shows that the caveolin-2 staining appears in apposition
to those pathogen cells that are at the inclusion mem-
brane (Figure 2, see Discussion).
In contrast to the above strains, C. trachomatis serovars A,
B, and C, do not enter via lipid rafts, and their inclusions
do not acquire caveolin-1 in HeLa cells [19]. Nevertheless,
in HeLa cells inclusions of each of these strains also
acquired caveolin-2 (Figure 1, Table 1). In our earlier
study, entry of strains LGV (L2) and MoPn was seen to be
independent of lipid rafts, and their inclusions were not
marked by caveolin-1. In the present study, their inclu-
sions did not display caveolin-2 and therefore they did
not accumulate this host protein during their develop-
ment (Figure 1, Table 1).
Caveolin-2 is present on chlamydial inclusions in caveolin-
1 negative FRT cells
Others have demonstrated that caveolin-2 is not trans-
ported out from the Golgi in caveolin-1 negative FRT cells,
but that expression of a transfected caveolin-1 gene in
those cells restores caveolin-2 transport [25,26]. These
experimental findings imply that caveolin-2 transport is
dependent on its association with caveolin-1. Thus, it was
somewhat surprising that during development in HeLa
cells, inclusions of C. trachomatis serovars A, B, and C
acquired caveolin-2 without acquiring caveolin-1. To con-
firm that chlamydial inclusions indeed could acquire
caveolin-2 independently of caveolin-1, we further exam-
ined infections using caveolin-1 negative FRT cells. Nor-
mally these cells do not express caveolin-1 or form
caveolae, but do so when transfected with caveolin-1
cDNA [27-29]. Inclusions of C. trachomatis serovars A, B,
C, E, F, and K, as well as C. pneumoniae, and C. caviae each
were marked by caveolin-2 in the caveolin-1 negative FRT
cells (Figure 3). This clearly confirms that trafficking of
caveolin-2 to chlamydial inclusions does occur independ-
ently of caveolin-1. Note that earlier we demonstrated
that among those we tested, MoPn and GPIC are the only
strains that develop large inclusions in FRT cells, and con-
firmed that these cells indeed do not express caveolin-1
[19].
To confirm the specificity of the caveolin-2 antibody for
the caveolin-2 protein in these cells, and to rule out the
possibility of cross-reactivity of this antibody with the
chlamydial EBs, we performed western blot on renografin
gradient purified EBs from C. pneumoniae and C. trachom-
atis and stained the blot with anti-caveolin-2 antibodies
(figure 4A). As seen in the representative blot, the caveo-
lin-2 antibody does not cross-react with purified EBs. This
is also true for anti-caveolin-1 antibodies (data not
shown). The presence of chlamydial EBs on the blot was
assessed by loading the same amount of EBs onto the sec-
ond half of the gel in figure 4A and staining with a rabbit
anti-Chlamydia serum (figure 4B). Note that there is ade-
quate material on this stained blot, confirming that if the
caveolin antibody was cross-reactive with EB material one
would be able to see such a reaction.
Acquisition of caveolin-2 by inclusions requires pathogen 
gene expression
The apparent inability of caveolin-2 to traffic from the
Golgi independently of caveolin-1 in uninfected cells
[25,26] implies that in a manner yet unknown, the
chlamydial inclusions might produce a factor thatBMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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Localization of chlamydial inclusions and caveolin-2 in HeLa cells Figure 1
Localization of chlamydial inclusions and caveolin-2 in HeLa cells. HeLa 229 cells were infected with chlamydial 
strains for 48 h. Cells were fixed and double stained with a rabbit anti-Chlamydia and a mouse anti-caveolin-2 antibody. Inclu-
sions of C. pneumoniae (AR39) Cpn, C. Psittaci (guinea pig inclusion conjunctivitis, GPIC strain), C. trachomatis serovars A/Har-
13, Har36B, C/TW-3, K, (E/VW-KX and F not shown), are seen to co-localize with caveolin-2. Itnclusions of C. trachomatis 
Mouse pnuemonitis agent (MoPn) and Lymphogranuloma venereum biovar (LGV 434) [not shown] do not colocalize with 
caveolin-2. Scale bar represents 25 µm and original magnification: 600X
Table 1: Comparative colocalization of the Chlamydiaceae with caveolin-1 and -2 Note that caveolin-2 colocalizes with all the inclusions 
that caveolin-1 colocalized with. In addition, caveolin-2 is seen associated with the inclusions of serovars, A, B and C, all ocular serovars, 
which did not colocalize with caveolin-1
Organisms Caveolin-1 Caveolin-2 Raft-mediated Entry
C. pneumoniae (AR 39) + + Yes
C. caviae (GPIC) + + Yes
C. trachomatis (MoPn) - - No
C. trachomatis (ser A) - + No
C. trachomatis (36 B) - + No
C. trachomatis (ser C) - + No
C. trachomatis (ser E) + + Yes
C. trachomatis (ser F) + + Yes
C. trachomatis (ser K) + + Yes
LGV (L2) -- N O
(+) colocalization; (-) no colocalizationBMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
Page 6 of 12
(page number not for citation purposes)
activates an additional sorting and transport process for
caveolin-2. To test this hypothesis, we asked whether UV-
inactivated EBs, the infectious form of the pathogen,
might sequester caveolin-2 on their vacuoles in caveolin-
1 negative FRT cells. Pathogen-containing vacuoles of
each of the strains indeed were unable to acquire caveolin-
2 when the EBs had been inactivated by UV irradiation
prior to infection. This result therefore supports the
premise that vacuole/inclusion acquisition of caveolin-2
is dependent on pathogen gene expression (Figure 5). In
caveolin-1 positive HeLa cells, a minimal amount of cave-
olin-2 protein was observed to co-localize to vacuoles
with UV-treated EBs (Figure 6, see Discussion).
Discussion
Experimental results presented here demonstrate that for
a number of chlamydial strains and species, the intracel-
lular inclusions indeed acquire caveolin-2 during the
developmental cycle. These strains include C. trachomatis
serovars A, B, C, E, F, and K, C. pneumoniae (A39), and
GPIC (Table 1). C. trachomatis serovars E, F, and K, and the
C. pneumoniae and C. caviae species of Chlamydophila pre-
viously were shown to enter host cells via lipid rafts. Their
vacuoles/inclusions were demonstrated to acquire host
cell caveolin-1 at entry and to accumulate it during later
stages of infection [18,19].
Consequently, in host cells that express both caveolin pro-
teins, inclusions of these strains display caveolin-2, as well
as caveolin-1. However, in this same cell type, inclusions
of serovars A, B, and C, are marked only by caveolin-2, a
result implying that for chlamydial inclusions this acqui-
sition can occur independently of caveolin-1. This impli-
cation is somewhat surprising since there is experimental
evidence demonstrating that caveolin-2 usually can not
exit from the Golgi and traffic to the plasma membrane in
the absence of caveolin-1[25,26]. However, if recom-
binant caveolin-1 DNA is expressed by caveolin-1
negative cells, then caveolin-2 can transit from the Golgi
and be delivered to the plasma membrane, as a hetero-oli-
gomeric complex with caveolin-1[25,26,30,31].
To confirm that transport of caveolin-2 to chlamydial
inclusions indeed might occur independently of caveolin-
1, we asked whether chlamydial inclusions might simi-
larly acquire caveolin-2 in FRT cells, a cell line that does
not express caveolin-1 [27-29]. In our earlier report [19],
we confirmed that FRT cells in fact do not express caveo-
lin-1. Also, we demonstrated that whereas for some
Optical Z-axis sections of caveolin-2 associated with chlamydial inclusion membranes Figure 2
Optical Z-axis sections of caveolin-2 associated with chlamydial inclusion membranes. FRT cells were infected 
with C. trachomatis serovar K for 48 h. Cells were fixed with 10% cold methanol and double stained with a guinea pig anti-
Chlamydia and a mouse anti-caveolin-2 antibody. The secondary antibodies were FITC-conjugated goat anti-mouse and TRITC-
conjugated goat anti-guinea pig antibody. Slides were examined using a laser confocal microscope and optical Z-axis sections 
were taken at 0.5 µm depth and images merged using the Confocal Assistant™ version 4.02 Image Processing Software. Origi-
nal magnification: 600X; the scale bar is 25 µm in length.BMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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Acquisition of caveolin-2 by inclusions in caveolin-1 negative FRT cells Figure 3
Acquisition of caveolin-2 by inclusions in caveolin-1 negative FRT cells. (A) FRT cells were infected with chlamydial 
organisms for 48 h. C. pneumoniae, C. psittaci, and C. trachomatis serovars A, B, E, K (not shown), as well as serovars C and F 
colocalized with caveolin-2. MoPn and LGV (not shown), did not colocalize with caveolin-2 in these cells. Note that only two 
species, the mouse pneumonitis strain (MoPn) and GPIC produce large inclusions in these cells even after 48 h infection (scale 
bar is 25 µm). The small inclusions nonetheless release viable progeny into the culture supernatant which could be used to 
infect new cells. (B) Uninfected FRT-cells stained with anti-caveolin-2 antibody to demonstrate the localization of caveolin-2 
protein in the cell. Note the caveolin-2 staining (C) close to the nucleus of the cell and that there is no caveolin in the cell 
membrane. (N), the nucleus of the cells and the scale bar represents 10 µm. Original magnification: 600XBMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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chlamydial strains, entry into those cells was dependent
on intact lipid rafts (Table 1), in no case was entry
dependent on caveolin-1 and caveolae. We show here that
in the caveolin-1 negative FRT cells, inclusions of each of
the above chlamydial strains in fact acquired caveolin-2.
Moreover, since FRT cells do not contain caveolin-2 at the
plasma membrane, pathogen-associated caveolin-2 could
not have been acquired at entry. Rather, it had to derive
from an intracellular source.
Chlamydial inclusions thus acquired caveolin-2 despite
the fact that in the absence of caveolin-1 this protein usu-
ally does not traffic from the Golgi. We therefore sug-
gested that the pathogen might influence the host cell and
actually induce a transport and sorting pathway that nor-
mally may not actively function in the uninfected cell.
Consistent with this suggestion is the fact that for all
strains and species tested in FRT cells, if the pathogens
were inactivated by prior EB treatment with UV irradia-
tion, none of the EB containing vesicles acquired caveolin-
2. In contrast, in HeLa cells, there were low levels of cave-
olin-2 associated with vesicles containing UV-treated EBs.
The source of these low levels of caveolin-2 on vesicles/
inclusions in HeLa cells is not yet clear. Perhaps the EBs
are acquiring minimal amounts of caveolin-2 from the
membranes of these cells upon entry. This suggestion is
supported by the fact that the vesicles of these UV irradi-
ated EBs contain both caveolin-1 and -2 (data not shown);
suggesting that the proteins might be co-localizing in het-
ero-oligomeric complexes.
It is well known that Chlamydia-containing vacuoles and
later, the developing inclusions, are able to intercept and
fuse with exocytic vesicles of the biosynthetic pathway
that originate from the Golgi [6,7]. These Golgi-derived
vesicles provide the inclusions with sphingolipids and
perhaps other key metabolites [7,32]. In addition, the
ability of at least some chlamydial strains to intercept
these Golgi-derived vesicles is dependent on pathogen
viability and therefore likely on gene expression. Consid-
ering these points, and the fact that caveolin-1/2 hetero-
oligomers traffic to the plasma membrane from the Golgi
[25,26,30,31], it is reasonable to suggest that the previ-
ously described pathogen induced interception of Golgi-
derived vesicles might account for the acquisition of cave-
olin-2 by inclusions, as seen in the current study. How-
ever, although studies by others indicate that all
chlamydial strains appear to intercept vesicles of the bio-
synthetic pathway, not all strains acquire caveolin-2 and
this fact provides a strong counter argument. Thus for
example, in the current study LGV (L2) inclusions did not
acquire caveolin-2 (Table 1), although they have been
reported to intercept Golgi-derived vesicles of the biosyn-
thetic pathway [7]. Furthermore, in the current study,
acquisition of caveolin-2 by inclusions of some strains
was independent of caveolin-1, while among other
strains, inclusions acquired both caveolin proteins. Thus
there may be more than one pathway by which inclusions
acquire caveolin-2. Importantly, acquisition of caveolin-2
by inclusions of any particular strain did not correlate
with entry by a raft-mediated pathway. In contrast, acqui-
sition of caveolin-1 at early as well as late stages in patho-
gen development did correlate with a route of entry
involving lipid raft microdomains. Together, these facts
are consistent with the conclusion that acquisition of
Anti-caveolin-2 antibodies do not cross-react with chlamydial  EBs Figure 4
Anti-caveolin-2 antibodies do not cross-react with 
chlamydial EBs. C. trachomatis serovar K and C. pneumoniae 
AR39 EBs were purified by renografin gradient and separated 
on a 10–12% NuPAGE gel. The proteins were transferred to 
a PVDF membrane, (A) stained with a mouse monoclonal 
anti-caveolin-2 antibody and the reacting complex detected 
with an AP-conjugated goat-anti-mouse secondary antibody. 
Mw is the molecular weight marker, Con is an endothelial 
cell lysates for caveolin-2 control, Cpn is C. pneumoniae EBs 
and Ct represents C. trachomatis EBs. Note that there is 
staining in the control lane at 22 kDa (caveolin), while there 
is no staining in the chlamydial organism lanes. (B) control 
blot using the same quantity and preparation of C. trachomatis 
serovar K and Cpn EBs as above. The blot was stained with a 
rabbit anti-Chlamydia polyclonal antibody.BMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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caveoloin-1 and -2 can represent independent and dis-
tinct processes. As expected, similar incubations with anti-
caveolin-3 demonstrated this component was not present
in any of these cells whether infected with Chlamydiae or
not.
To date, no chlamydial protein has been identified that
might be secreted into the host cell cytosol to influence
host intracellular trafficking. However, several chlamydial
proteins, termed Incs, have been identified in the inclu-
sion membrane [33-35]. Several of these Inc proteins have
cytoplasmic domains, making them potential mediators
for interactions with the host that might influence traffick-
ing [36]. One of these proteins, IncG, interacts with host
protein, 14-3-3β [37]. This particular interaction can not
underlie the trafficking of caveolin-2 to the inclusions
Ultraviolet-treated EBs do not colocalize with caveolin-2 in caveolin-1 negative FRT cells Figure 5
Ultraviolet-treated EBs do not colocalize with caveolin-2 in caveolin-1 negative FRT cells. Chlamydial EBs were 
treated with short wavelength UV for 1 h and then used to infect FRT HeLa cells for 36 h. The cells were fixed and stained 
with a mouse anti-caveolin-2 and a guinea pig anti-Chlamydia antibody. FITC-conjugated goat anti-mouse as well as TRITC-con-
jugated goat anti-guinea pig secondary antibody was used to visualize the stained EBs. The representative confocal micrographs 
above show that UV-treated EBs did not colocalize with caveolin-2 in FRT cells. All of the Chlamydiaceae not shown had a sim-
ilar morphology. Scale bar represents 15 µm Original magnification: 600XBMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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since GPIC (C. caviae) and C. pneumoniae (AR39) do not
express IncG [37], although, as shown here, they do
acquire caveolin-2. Furthermore, the reverse also is true.
Thus, as demonstrated above, mouse pneumonitis strain,
MoPn and LGV (L2) do not acquire caveolin-2, but they
do express IncG [37]. There are, however, other Inc
proteins and they may underlie the phenomena we have
presented here.
Despite their presence on chlamydial inclusions, it
remains unclear what role, if any, caveolin proteins may
play in the developmental cycle of Chlamydia. As noted
above, all ten of the chlamydial strains and species we
examined were able to enter caveolin-1 negative FRT cells
[19]. Since these caveolin-1 negative cells do not express
caveolin-2 at the plasma membrane [25,26], it would
appear that for any of these strains neither of the caveolin
proteins is necessary for entry per se. Although following
Ultraviolet-treated EBs colocalize with caveolin-2 in HeLa cells Figure 6
Ultraviolet-treated EBs colocalize with caveolin-2 in HeLa cells. Chlamydial EBs were treated with UV light for 1 h 
and then used to infect HeLa 229 HeLa cells for 36 h. The cells were fixed and stained with a mouse anti-caveolin-2 and a 
guinea pig anti-Chlamydia antibody. A FITC-conjugated goat anti-mouse antibody and a TRITC-conjugated goat anti-guinea pig 
secondary antibody were used to visualize the stained EBs. Unlike the case in FRT cells, UV-treated EBs colocalized with cave-
olin-2 in HeLa cells, which express both Caveolin-1 and Caveolin-2. The above confocal micrographs are representative of the 
morphology of all Chlamydiaceae that colocalize with caveolin-2 (C. pneumoniae, GPIC, and C. trachomatis serovars A, B, C, E, F 
and K). Original magnification: 600 X. Each scale bar represents 15 µm.BMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
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internalization all ten strains and species remained viable
in the FRT cells [19], the only strains able to generate large
inclusions in the FRT cells were GPIC which acquires both
caveolin-1 and -2 in caveolin-positive cells, and MoPn
which acquires neither caveolin protein. Despite these lat-
ter two instances, our findings remain consistent with the
possibility that caveolin-1 may yet play a post entry role in
the development of at least some strains. The fact that suc-
cessful MoPn development does occur in inclusions that
acquire neither caveolin-1 nor -2 [19] (and current study)
could mean that neither caveolin-1 nor -2 has a necessary
role in the development of MoPn. The ability of GPIC to
develop mature inclusions in FRT cells where it acquires
only caveolin-2, despite acquiring both caveolin proteins
in caveolin-1 positive cells, may imply that for GPIC cave-
olin-2 rather than caveolin-1 is a key for development.
Likewise, inclusions of C. trachomatis serovars A, B, and C,
whether developing in HeLa or FRT cells, display only
caveolin-2, suggesting a potentially broader chlamydial
requirement for the caveolin-2 protein during
development.
The series of merged optical sections demonstrating the
association of caveolin-2 with the inclusions (Figure 2)
implies that caveolin-2 is in apposition to pathogen cells
that are located at the inclusion membrane. Nevertheless,
the caveolin-2 is not in direct contact with the pathogens.
Caveolin is not a transmembrane protein, a fact that can
be deduced from the experimental finding that cell-sur-
face biotinylation does not label caveolin proteins [38].
Thus, these membrane proteins are not accessible from
the extracellular milieu, and this originally extracellular
membrane surface, is topologically equivalent to the
lumen of the chlamydial inclusion. Hence, whereas our
findings imply a specific association between the patho-
gens and caveolin-2, this association appears to be indi-
rect. The paucity of information concerning caveolin-2
does not enable us to suggest an identity for the linking
molecule. Moreover, how this indirect association
between caveolin-2 and the pathogen might relate to the
protein's function in the chlamydial developmental cycle,
or in its acquisition by the pathogen, is also not yet clear.
Conclusions
Among the Chlamydiae, depending on the serovar, or the
species, one or both of the caveolin proteins may play an
important role in the developmental cycles. Further stud-
ies of the interaction of the Chlamydiae with these enig-
matic host cell proteins may well help to clarify caveolin
functions in the host cell. Likewise, such studies may indi-
cate factors influencing caveolin expression and traffick-
ing from the Golgi, and elucidate their significance to the
developmental cycle of these pathogens. The function of
caveolin-2, either in the uninfected cell or in the chlamy-
dial developmental cycle, remains to be elucidated. Nev-
ertheless, this second caveolin protein can now be added
to the small number of host proteins that are reported as
associated with the inclusions of this obligate intracellular
pathogen.
Competing interests
None Declared.
Authors' contributions
ES and LN conceived of the study and participated in its
design and coordination. LN was instrumental in the
design of the study and prepared the initial draft of the
manuscript. WW carried out all the experimental work,
took photographs, did statistical analyses where neces-
sary, and participated in the design and coordination of
the project. All authors contributed to the preparation of
the final manuscript.
Acknowledgements
We thank Michael P. Lisanti for providing wild type FRT cells and FRT cells 
that express caveolin-1, Judy Whittum-Hudson for providing C. trachomatis 
serovars C, E and LGV (L2), and Roger G. Rank for providing C. trachomatis 
(MoPn). This material was supported by the Cooperative State Research 
Extension, Education Service, U.S. Department of Agriculture, Massachu-
setts Agricultural Experiment Station, under Project. MAS00845. The Uni-
versity of Massachusetts Central Microscopy Facility is supported by a grant 
from the National Science Foundation (NSF BBS 8714235). Wilmore C. 
Webley was supported in part by a Fulbright Scholarship.
References
1. Friis RR: Interaction of L cells and Chlamydia psittaci: entry of
the parasite and host responses to its development. J Bacteriol
1972, 110:706-721.
2. Lawn AM, Blyth WA, Taverne J: Interactions of TRIC agents with
macrophages and BHK-21 cells observed by electron
microscopy. J Hyg (Lond) 1973, 71:515-528.
3. Wyrick PB, Brownridge EA: Growth of Chlamydia psittaci in
macrophages. Infect Immun 1978, 19:1054-1060.
4. Clausen JD, Christiansen G, Holst HU, Birkelund S: Chlamydia tra-
chomatis utilizes the host cell microtubule network during
early events of infection. Mol Microbiol 1997, 25:441-449.
5. Campbell S, Richmond SJ, Yates PS: The effect of Chlamydia tra-
chomatis infection on the host cell cytoskeleton and mem-
brane compartments.  J Gen Microbiol 1989, 135 ( Pt
9):2379-2386.
6. Hackstadt T, Scidmore MA, Rockey DD: Lipid metabolism in
Chlamydia trachomatis-infected cells: directed trafficking of
Golgi-derived sphingolipids to the chlamydial inclusion. Proc
Natl Acad Sci U S A 1995, 92:4877-4881.
7. Hackstadt T, Rockey DD, Heinzen RA, Scidmore MA: Chlamydia
trachomatis interrupts an exocytic pathway to acquire
endogenously synthesized sphingomyelin in transit from the
Golgi apparatus to the plasma membrane.  Embo J 1996,
15:964-977.
8. Heinzen RA, Scidmore MA, Rockey DD, Hackstadt T: Differential
interaction with endocytic and exocytic pathways distinguish
parasitophorous vacuoles of Coxiella burnetii and Chlamy-
dia trachomatis. Infect Immun 1996, 64:796-809.
9. Scidmore MA, Fischer ER, Hackstadt T: Sphingolipids and glyco-
proteins are differentially trafficked to the Chlamydia tra-
chomatis inclusion. J Cell Biol 1996, 134:363-374.
10. Everett KD, Bush RM, Andersen AA: Emended description of the
order Chlamydiales, proposal of Parachlamydiaceae fam.
nov. and Simkaniaceae fam. nov., each containing one mono-
typic genus, revised taxonomy of the family Chlamydiaceae,
including a new genus and five new species, and standards forPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2004, 4:23 http://www.biomedcentral.com/1471-2334/4/23
Page 12 of 12
(page number not for citation purposes)
the identification of organisms. Int J Syst Bacteriol 1999, 49 Pt
2:415-440.
11. Pal S, Theodor I, Peterson EM, de la Maza LM: Immunization with
the Chlamydia trachomatis mouse pneumonitis major outer
membrane protein can elicit a protective immune response
against a genital challenge. Infect Immun 2001, 69:6240-6247.
12. Morrison RP, Caldwell HD: Immunity to murine chlamydial
genital infection. Infect Immun 2002, 70:2741-2751.
13. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE: Pelvic
inflammatory disease and fertility. A cohort study of 1,844
women with laparoscopically verified disease and 657 con-
trol women with normal laparoscopic results. Sex Transm Dis
1992, 19:185-192.
14. Thylefors B: A global initiative for the elimination of avoidable
blindness. Indian J Ophthalmol 1998, 46:129-130.
15. Byrne GI, Kalayoglu MV: Chlamydia pneumoniae and athero-
sclerosis: links to the disease process.  Am Heart J 1999,
138:S488-90.
16. Campbell LA, Kuo CC, Grayston JT: Chlamydia pneumoniae and
cardiovascular disease. Emerg Infect Dis 1998, 4:571-579.
17. Simons K, Ikonen E: Functional rafts in cell membranes. Nature
1997, 387:569-572.
18. Norkin LC, Wolfrom SA, Stuart ES: Association of caveolin with
Chlamydia trachomatis inclusions at early and late stages of
infection. Exp Cell Res 2001, 266:229-238.
19. Stuart ES, Webley WC, Norkin LC: Lipid rafts, caveolae, caveo-
lin-1, and entry by Chlamydiae into host cells. Exp Cell Res
2003, 287:67-78.
20. Matveev S, Li X, Everson W, Smart EJ: The role of caveolae and
caveolin in vesicle-dependent and vesicle-independent
trafficking. Adv Drug Deliv Rev 2001, 49:237-250.
21. Brown DA, Rose JK: Sorting of GPI-anchored proteins to gly-
colipid-enriched membrane subdomains during transport to
the apical cell surface. Cell 1992, 68:533-544.
22. Dupree P, Parton RG, Raposo G, Kurzchalia TV, Simons K: Caveolae
and sorting in the trans-Golgi network of epithelial cells.
Embo J 1993, 12:1597-1605.
23. Lisanti MP, Tang ZL, Sargiacomo M: Caveolin forms a hetero-oli-
gomeric protein complex that interacts with an apical GPI-
linked protein: implications for the biogenesis of caveolae. J
Cell Biol 1993, 123:595-604.
24. Galbiati F, Razani B, Lisanti MP: Emerging themes in lipid rafts
and caveolae. Cell 2001, 106:403-411.
25. Mora R, Bonilha VL, Marmorstein A, Scherer PE, Brown D, Lisanti MP,
Rodriguez-Boulan E: Caveolin-2 localizes to the golgi complex
but redistributes to plasma membrane, caveolae, and rafts
when co-expressed with caveolin-1.  J Biol Chem 1999,
274:25708-25717.
26. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA,
Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E,
Peschle C, Lisanti MP: Expression of caveolin-1 is required for
the transport of caveolin-2 to the plasma membrane. Reten-
tion of caveolin-2 at the level of the golgi complex. J Biol Chem
1999, 274:25718-25725.
27. Lipardi C, Mora R, Colomer V, Paladino S, Nitsch L, Rodriguez-Boulan
E, Zurzolo C: Caveolin transfection results in caveolae forma-
tion but not apical sorting of glycosylphosphatidylinositol
(GPI)-anchored proteins in epithelial cells.  J Cell Biol 1998,
140:617-626.
28. Sargiacomo M, Sudol M, Tang Z, Lisanti MP: Signal transducing
molecules and glycosyl-phosphatidylinositol-linked proteins
form a caveolin-rich insoluble complex in MDCK cells. J Cell
Biol 1993, 122:789-807.
29. Zurzolo C, van't Hof W, van Meer G, Rodriguez-Boulan E: VIP21/
caveolin, glycosphingolipid clusters and the sorting of glyco-
sylphosphatidylinositol-anchored proteins in epithelial cells.
Embo J 1994, 13:42-53.
30. Das K, Lewis RY, Scherer PE, Lisanti MP: The membrane-span-
ning domains of caveolins-1 and -2 mediate the formation of
caveolin hetero-oligomers. Implications for the assembly of
caveolae membranes in vivo. J Biol Chem 1999, 274:18721-18728.
31. Scheiffele P, Verkade P, Fra AM, Virta H, Simons K, Ikonen E: Cave-
olin-1 and -2 in the exocytic pathway of MDCK cells. J Cell Biol
1998, 140:795-806.
32. Carabeo RA, Mead DJ, Hackstadt T: Golgi-dependent transport
of cholesterol to the Chlamydia trachomatis inclusion. Proc
Natl Acad Sci U S A 2003, 100:6771-6776.
33. Rockey DD, Heinzen RA, Hackstadt T: Cloning and characteriza-
tion of a Chlamydia psittaci gene coding for a protein local-
ized in the inclusion membrane of infected cells. Mol Microbiol
1995, 15:617-626.
34. Bannantine JP, Stamm WE, Suchland RJ, Rockey DD: Chlamydia
trachomatis IncA is localized to the inclusion membrane and
is recognized by antisera from infected humans and
primates. Infect Immun 1998, 66:6017-6021.
35. Scidmore-Carlson MA, Shaw EI, Dooley CA, Fischer ER, Hackstadt T:
Identification and characterization of a Chlamydia trachom-
atis early operon encoding four novel inclusion membrane
proteins. Mol Microbiol 1999, 33:753-765.
36. Hackstadt T, Scidmore-Carlson MA, Shaw EI, Fischer ER: The
Chlamydia trachomatis IncA protein is required for homo-
typic vesicle fusion. Cell Microbiol 1999, 1:119-130.
37. Scidmore MA, Hackstadt T: Mammalian 14-3-3beta associates
with the Chlamydia trachomatis inclusion membrane via its
interaction with IncG. Mol Microbiol 2001, 39:1638-1650.
38. Sargiacomo M, Scherer PE, Tang Z, Kubler E, Song KS, Sanders MC,
Lisanti MP: Oligomeric structure of caveolin: implications for
caveolae membrane organization. Proc Natl Acad Sci U S A 1995,
92:9407-9411.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/4/23/prepub